Healthcare Assets are a Lucrative Target
A highly lucrative target But chronic underspending by providers and ease of access to their networks only partially accounts for the rise of healthcare system cyber attacks. The healthcare sector…
Throughout the current cycle, the healthcare sector has been a major source of growth for both the economy and investors. Over the past five years, healthcare expenditure has outpaced U.S.…
In 4Q15, Danaher’s (DHR) adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) was ~$1.4 billion, while its EBITDA margin was 23.3%.
DHR’s interest expenses fell sharply in 3Q16 due to the allocation of a portion of its consolidated interest expense to its discontinued operations (FTV).
Danaher (DHR) reported ~$5.9 billion in consolidated revenue in 4Q15. Analysts expect DHR to report $4.5 billion in 4Q16 revenue.
Of the 19 analysts covering Danaher, 15 had given the company “buy” ratings, four had given it “hold” ratings, and none had given it “sell” ratings as of January 12, 2017.
Danaher Corporation (DHR) will announce its 4Q16 earning results before the market opens on January 31, 2017. What should we expect?
As of January 11, 2017, ISRG stock was trading 35.0% above its 52-week low of $502.01 on February 9, 2016.
On December 13, 2016, Intuitive Surgical increased its authorized share repurchase program from $1.0 billion to $3.0 billion.
Intuitive Surgical expects about a 15.0% procedure growth in fiscal 2016, which is expected to boost the company’s earnings.
Intuitive Surgical (ISRG) announced preliminary results for fiscal 4Q16 on January 11, 2017. The company expects to report higher-than-expected revenues.
Intuitive Surgical (ISRG), the leader in the surgical robotics industry, is set to release its 4Q16 results on January 24, 2017. About 68.4% of analysts rate it a “buy,”
Of the 23 broker firms in Reuters’ survey, JNJ received “buy” ratings from ~39% of the firms, while ~61% of the firms rated the company a “hold.”
JNJ announced a quarterly cash dividend of $0.80 per share on January 3. This payment represents a dividend growth rate of 6.7% over the previous year.
JNJ posted better-than-expected 2Q16 earnings results on July 20, 2016. But its share price has fallen ~2% since October 18, 2016.
On January 3, DePuy Synthes, a subsidiary of Johnson & Johnson (JNJ), entered into an asset purchase and development agreement with Interventional Spine.
Johnson & Johnson (JNJ) has faced many litigations over the years, the most serious of which being its faulty hip replacement system lawsuits.
In 3Q16, Johnson & Johnson (JNJ) reported sales of $17.8 billion, representing a YoY (year-over-year) growth of ~4.2%.
On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.
Zimmer Biomet Holdings (ZBH) was trading at $104.9 as of January 5, 2017. It has a 50-day moving average of $102.9 and a 200-day moving average of $118.5.